1393 results about "Serine" patented technology

The invention relates to the technical field of microbial fermentation, and discloses a genetically engineered bacterium of high-yield D-pantothenic acid as well as a preparation method and application of the genetically engineered bacterium. The D-PA yield of the engineering bacteria is greatly improved through the following effects that acetolactate synthase IlvB and IlvN shunted by pyruvic acid are subjected to overexpression, meanwhile, a transcription attenuation region is deleted, and valine feedback inhibition sites are mutated; the method comprises the following steps: overexpressing keto-alcohol acid reductoisomerase IlvC and dihydroxy acid dehydratase IlvD, and converting the IlvC coenzyme preference from NADPH into NADH, so as to break through the upstream of D-PA synthesis; overexpression of PanB is carried out, overexpression of a serine-glycine transport system is carried out, and synthesis of 5, 10-methylenetetrahydrofolic acid is promoted; meanwhile, the expression of ketopantoic acid reductase PanE is enhanced; and finally, over-expressing pantothenic acid synthetase PanC, and increasing the content of a cofactor ATP required by the PanC. According to the engineering bacteria provided by the invention, through overall reinforcement of the multiple modules, cell growth is improved due to balance of cofactors and increase of D-PA, and the yield of D-PA reaches an unprecedented height.

The invention relates to the field of gene engineering, and discloses a D-3-phosphoglycerate dehydrogenase mutant, a coding gene thereof and application of the D-3-phosphoglycerate dehydrogenase mutant and the coding gene. Compared with a protein with an amino acid sequence as shown in SEQ ID NO: 1, the mutant comprises mutation at the 131 site and / or the 285 site. The mutant can specifically catalyze a substrate 3-phosphoglycerate to synthesize 3-phosphate-hydroxypyruvic acid, can effectively promote synthesis of L-serine in a metabolic pathway of microorganisms, improves the yield and conversion rate of the L-serine, and reduces the yield of byproducts at the same time.

The invention relates to the technical field of daily chemicals, in particular to a hair repairing agent and application thereof. The shampoo is prepared from the following raw materials: a suspending agent, a surfactant, a hair conditioner, a solvent, a cleaning agent, a functional repairing agent, a preservative, an aromatic, a thickening agent and a humectant. Fibroin is degummed through bifidus yeast by adopting a biological fermentation technology to obtain a protein active matter with lower molecular weight, a fibroin derivative is rich in a large amount of amino acid, glycine, alanine and serine account for about 85% of the total composition, the fibroin derivative has very strong moisturizing performance, the extract can rapidly permeate into hair cores, and the effect of moisturizing the hair cores is achieved. The water bonding capability of hair is enhanced, naturally existing free amino acids and lost polypeptides are supplemented, the fiber structure of the hair is recombined, the strength, toughness and glossiness of the hair are enhanced, and branching and embrittlement are prevented.

The invention discloses a high-performance carbonyl reductase mutant and application thereof in synthesis of a series of chiral alcohols. The high-performance carbonyl reductase mutant is obtained by performing the following mutations on an amino acid sequence as shown in SEQ ID NO.2: the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine, and the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine; and / or the 100th glycine is mutated into any one of glutamic acid, serine, lysine or asparagine. Compared with a wild type enzyme, the thermal stability and the catalytic activity of the obtained mutant are remarkably improved, particularly, single point mutants Mut-A69N, Mut-G100E and Mut-G100N and a combined mutant Mut-A69N-G100N show excellent relative enzyme activity, thermal stability and substrate tolerance. The mutant has high catalytic activity and stability to various chiral alcohols, and the contradiction that the traditional carbonyl reductase is easy to inactivate at high temperature and the catalytic efficiency is difficult to achieve at the same time is solved. The invention provides an efficient and stable enzyme catalysis tool for green biological preparation of chiral drug intermediates.

The invention belongs to the field of bioengineering, and particularly discloses a tryptophan synthetase mutant with improved enzymatic activity and application of the tryptophan synthetase mutant in production of L-cysteine. Compared with wild tryptophan synthetase from escherichia coli, the amino acid sequence of the tryptophan synthetase mutant has the advantages that a beta catalytic subunit has T69A, S143A, R219E and F280H site combined mutation. Researches show that the enzyme activity of the mutant is increased by 2.4 times compared with that of a wild type through enzyme activity determination and analysis of inducible expression and purification. The beneficial tryptophan synthetase mutant provided by the invention can efficiently biocatalyze L-serine and sodium hydrosulfide to synthesize L-cysteine, and has a better industrial application prospect.

The invention relates to the technical field of gene engineering and enzyme engineering, in particular to an esterase mutant for degrading ethyl carbamate and application of the esterase mutant, the esterase mutant has an amino acid sequence as shown in SEQ ID NO.1 which is subjected to site mutation, the site mutation is any one or more site combined mutation of V129S, V161L or I229M, and the amino acid sequence of the esterase mutant is shown in SEQ ID NO.1. The V129S site mutation is that valine at the 129 site is mutated into serine, the V161L site mutation is that valine at the 161 site is mutated into leucine, and the I229M site mutation is that isoleucine at the 229 site is mutated into methionine. Mutation is carried out through a site-directed mutagenesis method, so that the amino acid sequence of the esterase mutant V129S / I229M is changed, the autoplasmic structure and function of eggs are changed, the esterase mutant V129S / I229M with the ethyl carbamate hydrolysis rate increased to 6.55 times in an acid environment is finally obtained, and the esterase mutant V129S / I229M has high industrial application value.

The invention discloses a tryptophan synthase mutant as well as a coding gene, a vector, recombinant bacteria and application thereof. Comprising the following steps: carrying out error-prone PCR (Polymerase Chain Reaction) on a coding gene trpBA of TrpS from EscherichiaoliK12MG1655, screening mutants by combining high-throughput screening, and finding that the affinity of the TrpS to a substrate indole can be effectively improved by mutating 114-site Gln of a beta subunit of the TrpS into Met and mutating 84-site Gly into Ser, so that the synthesis of L-tryptophan is promoted. The efficiency of the TrpS for converting indole and L-serine into L-tryptophan is higher due to the improvement of the affinity of indole. A new idea is provided for efficient production of L-tryptophan in the fermentation industry.

The invention belongs to the field of enzymatic preparation of structural phospholipids, and particularly relates to a method for preparing phosphatidylserine through interfacial enzyme catalysis. A series of high-activity immobilized phospholipase are prepared by innovatively adopting bifunctional group modified hollow mesoporous silica microspheres as a carrier and adsorbing immobilized phospholipase D. The catalyst has the functions of a catalyst and an emulsifier, and a Pickering emulsion interfacial enzyme catalysis system can be efficiently constructed. In the system, the phosphatidylcholine and the serine are efficiently converted into the phosphatidylserine through a phosphatidyl transfer reaction, the conversion rate of the phosphatidylserine within 20 minutes can reach 85%-95%, and the catalytic efficiency reaches up to 372 mmol / (g.h). In addition, after the catalyst is recycled for 10 times, the conversion rate is still kept at 70.9%, and the catalyst shows excellent stability and reusability. The method has the remarkable advantages of being mild in reaction condition, high in catalytic efficiency, capable of being repeatedly used and the like, and a new technical approach is provided for industrial production of phosphatidylserine.

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention relates to the technical field of microbial metabolism engineering, in particular to a construction method and application of genetically engineered bacteria for efficiently producing O-acetyl-L-homoserine. The construction method specifically comprises the following steps: (1) taking a strain Escherichia coli W3110 as a chassis, and knocking out a homoserine O-succinyl transferase coding gene metA; (2) knocking out a gamma-cystathionine synthetase encoding gene metB; (3) knocking out a cysteine lyase coding gene metC; (4) carrying out weakening expression on an O-acetyl-L-homoserine thiolase coding gene metYcm from the marine cyclobacterium; (5) overexpressing a ribulose diphosphate carboxylase coding gene rbcLSse from the synechococcus elongate; (6) overexpressing a ribulose phosphate kinase coding gene prkse from the synechococcus slender; and (7) weakening the expression of the citrate synthase coding gene gltA to obtain the genetically engineered bacterium for efficiently producing the O-acetyl-L-homoserine. The strain provided by the invention is used for producing O-acetyl-L-homoserine, and has the advantages of high yield, high yield and high sugar-acid conversion rate.

The invention provides a method for preparing high-purity phosphatidylserine by a batch enzyme catalysis method based on dynamic choline removal, and belongs to the technical field of enzymatic reaction. According to the method disclosed by the invention, in a reaction system for preparing phosphatidylserine, a byproduct choline is selectively adsorbed by adopting resin. Choline in a reaction system is removed in real time through the integrated adsorption separation module, the enzyme inhibition problem is solved, and meanwhile, the PC conversion rate is larger than or equal to 98% and the PS purity is larger than or equal to 96% in combination with the immobilized enzyme circulation technology; the enzyme can be reused for more than or equal to 20 times (activity retention is more than or equal to 90%); and the choline residual concentration is less than or equal to 0.5 mM (an inhibition threshold value or less).

The present invention discloses a complete medium for culturing DF-1 cells, including DMEM basal medium 13.7g / L, insulin, non-essential amino acids, transferrin, glutathione, ascorbyl phosphate, sodium selenite, ethanolamine, hydrocortisone, and newborn calf serum. Wherein non-essential amino acids include glycine, alanine, proline, serine, and asparagine. A complete medium for culturing DF-1 cells provided by the present invention can well promote the proliferation of DF-1 cells, can achieve the same proliferation effect as high-concentration fetal bovine serum, and is suitable for the adherent culture of DF-1 cells; using low-concentration newborn calf serum, it is possible to greatly avoid the batch differences, unstable culture results, cytotoxicity, and high risk of carrying pathogens brought by the culture medium with high-concentration serum, narrow application range, expensive fetal bovine serum, and high culture cost; the components are simple, the culture medium preparation process is short in time consumption, the culture efficiency is high, the repeatability is good, and it is suitable for batch production.

The invention discloses a diagnosis model for hepatocellular carcinoma microvascular invasion and a construction method and application thereof, and belongs to the technical field of medical examination. Metabolite in the blood of a hepatocellular carcinoma patient is taken as a cut-in, preoperative clinical tumor indexes are combined, it is found that PIVKA-II, GGT, L-Serine, Sarcosine and tumor sizes have important significance on formation of hepatocellular carcinoma MVI, a diagnosis model based on multiple omics and multiple dimensions is established based on the diagnosis indexes, the diagnosis model is used for diagnosis of the preoperative MVI of the hepatocellular carcinoma patient, and the diagnosis model is used for diagnosis of the preoperative MVI of the hepatocellular carcinoma patient. The defects of existing diagnosis means in the aspect of preoperative diagnosis are overcome, and a more timely and accurate basis is provided for clinical decision making.

The invention provides a target antibody or an antigen binding fragment thereof and application thereof, and belongs to the field of antibodies. Wherein the antibody or the antigen binding fragment thereof comprises a heavy chain complementarity determining region HCDR, and the HCDR comprises at least one selected from SEQ ID NO: 1-18 or an amino acid sequence having at least 80% homology with the HCDR. The antibody or the antigen-binding fragment thereof can bind to TIM-1 protein with high specificity and affinity, increase the blocking of TIM-1 activity so as to enable the TIM-1 to interact with ligands such as phosphatidylserine, TIM-4 and galectin-9, and enhance immune response.

The invention discloses keratinase Phyto-Keratinase and application of the keratinase Phyto-Keratinase. The keratinase Phyto-Keratinase comprises the following components: (1) protease which is coded by a nucleotide sequence as shown in SEQ ID NO.1; and / or (2) protease which is derived from bacillus subtilis, is coded by a nucleic acid sequence with more than 98% of identity with the SEQ ID NO.1 nucleotide sequence and has the characteristic of hydrolyzing keratin. According to the plant keratinase Phyto-Keratinase disclosed by the invention, the Phyto-Keratinase (plant keratinase) produced by utilizing microbial fermentation is a serine proteolytic enzyme, is also a biocompatible cutinase, and is obtained by fermenting saccharomyces cerevisiae. Phyto-Keratinase provides a nitrogen source for the growth of plants (beans), and contains various amino acids (functional peptides) and special proteolytic enzymes derived from the plants at the same time. The Phyto-keratinase can provide the effects of resisting inflammation, removing cutin and providing nutrition for skin regeneration at the same time, can relieve various inflammations by inhibiting PAR-2 receptors, and has potential value in the fields of cosmetics, beauty medicine and environment.

The invention provides a drug permeability clinical prediction model, a construction method thereof and a non-specific drug permeability evaluation method, and belongs to the technical field of biological medicine. The invention provides a construction method of a drug permeability clinical prediction model. According to the construction method, intestinal microorganism characteristics are introduced into model construction for the first time. The prediction performance of the constructed LGBM model containing the intestinal microorganism characteristics in the aspect of NAC permeability prediction is superior to that of other traditional business models. The invention also provides a serine-derived sphingolipid de novo synthesis pathway, which is different from the traditional sphingolipid de novo synthesis pathway, and is named as a cysteine sphingolipid metabolism pathway, NAC-derived cysteine may participate in the biosynthesis of microbial sphingolipid through covalent binding with palmitoyl-CoA, thereby damaging intestinal permeation of NAC.

The invention belongs to the technical field of mRNA vaccines, and particularly relates to a self-replicating mRNA vaccine as well as a preparation method and application thereof. The self-replicating mRNA is transcribed from an alphavirus skeleton vector, the alphavirus skeleton vector comprises gene sequences of alphavirus non-structural proteins nsP2, nsP3 and nsP4 and mutated nsP1, and cysteine at the 492nd position of the mutated nsP1 is mutated into serine. The self-replicating mRNA provided by the invention has higher expression quantity and longer expression time for the target gene. The self-replicating mRNA is used for expressing IMP3 and can be prepared into a vaccine with good prevention and treatment effects on IMP3 positive tumors. Therefore, the invention has a good application prospect in the development of medicines and vaccines.

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

The invention relates to the technical field of carotenoid cleavage dioxygenase, and discloses a carotenoid cleavage dioxygenase mutant and application thereof. In order to improve the efficiency of converting carotenoid in tobacco into aroma molecule beta-ionone, specific mutation of characteristic sites is carried out on carotenoid cleavage dioxygenase (PhCCD1) from petunia, that is, serine (S) at the 428 site of the carotenoid cleavage dioxygenase is mutated into cysteine (C) or tyrosine (Y) to obtain a mutant S428C or S428Y, and the mutant S428C or S428Y is converted into beta-ionone. The yield of the beta-ionone converted from the carotenoid is greatly improved. Experiments prove that the yields of beta-ionone of S428C and S428Y respectively reach 54.2 mg / L and 50.6 mg / L, which are respectively increased by 69.7% and 58.5% compared with those of a wild strain WT.

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention belongs to the technical field of enzyme engineering, and particularly relates to a protease mutant with a wide pH application range and application of the protease mutant to preparation of collagen peptide. The protease mutant disclosed by the invention is obtained by mutation on the basis of an original sequence of serine protease. The optimal degradation activity of the protease mutant to collagen is equivalent to that before mutation, and the protease mutant has a wider application range to pH conditions in reaction. The protease mutant can enhance the collagen extraction rate, simplify the process and reduce the process cost, and has a very good application prospect.

The invention relates to a TaCBL4 mediated TaSOS1 phosphorylation regulation and control site in wheat and an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation and control site. The TaSOS1 phosphorylation regulation and control site is Ser978-Ser1126 / Ser1128 (S978-DSPS); the phosphorylation regulation and control site of the TaSOS1 is S978-DSPS, and serine at the site 978 of the TaSOS1-DAA (S1126AS1128A) is mutated into alanine. The TaSOS1 in the wheat is from a chromosome LOC778390, NC057800.1 (13146069..13157356) of the 3A of the common wheat, and the TaSOS1 in the wheat is from a chromosome NC057800.1 (13146069..13157356). The invention also relates to an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation site Ser978-Ser126 / Ser128 (S978-DSPS) in the wheat as a molecular marker for detecting the salt tolerance of the wheat, and also relates to an application of the TaCBL4 mediated TaSOS1 phosphorylation regulation site. The site is applied to the aspects of wheat salt tolerance improvement and assisted breeding.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention discloses an euphausia superba oligopeptide nutritional composition for promoting neural development and application thereof, and belongs to the technical field of functional foods.The nutritional composition is prepared from, by weight, 0.01-10 parts of docosahexaenoic acid, 0.01-20 parts of arachidonic acid, 0.01-10 parts of phosphatidylserine and 0.01-80 parts of euphausia superba oligopeptide. The antarctic krill oligopeptide is obtained by treating antarctic krill, antarctic krill powder or degreased antarctic krill powder by utilizing an enzymolysis method, and the content of a peptide fragment with the molecular weight of less than 1000Da in the antarctic krill oligopeptide is more than 90%. The raw materials of the composition are easy to obtain, the safety is high, and the composition can be used for preparing products with the function of promoting neurodevelopment and can be taken as common food, health care products or medicines for a long time.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

Among other things, provided herein are systems that replace the natural random integration activity of a retrovirus with site-specific integration machinery. This approach allows for a more precise targeting of a gene of interest into a human genome, e.g., for therapeutic purposes. The system may include integration-deficient retrovirus (e.g., lentivirus) (IDLV), in which the natural integration activity has been reduced (e.g., by mutation to the viral integrase polypeptide). Instead, the system may comprise a site-specific recombinase (e.g., a serine recombinase, e.g., a serine integrase) capable of directing insertion of a template DNA, or portion thereof, into a desired site in the human genome.

The invention belongs to the technical field of triple negative breast cancer, and particularly relates to application of a polypeptide capable of specifically blocking phosphorylation of metabolic enzyme PSAT1S337 and functional remodeling of PSAT1 in preparation of a triple negative breast cancer treatment product. The phosphorylated polypeptide targeting PSAT1S337 is designed, and it is found that the polypeptide obviously inhibits growth of triple negative breast cancer tumors and can improve the curative effect of anti-PD-1 immunotherapy at the animal level. Meanwhile, the invention further provides application of the reagent for detecting the phosphorylation level of the PSAT1S337 and / or the hydroxylation level of the GPX4P159 in preparation of products for diagnosing and prognosing the triple negative breast cancer. The invention discloses a molecular mechanism of functional remodeling of the serine metabolic enzyme PSAT1 in occurrence and development of cell ferroptosis and triple negative breast cancer, and provides a new thought and an effective scheme for research and development of anti-tumor drugs for targeted serine metabolism reprogramming and early diagnosis of tumors.

The invention discloses an Escherichia coli endogenous alcohol dehydrogenase EcYjgB mutant and application thereof. The mutant is obtained by performing any one of the following mutations (a) to (c) on Escherichia coli endogenous alcohol dehydrogenase EcYjgB as shown in SEQ ID NO.1: (a) mutating serine at the 200th site into arginine; (b) the serine at the 199th site is mutated into aspartic acid, and the serine at the 200th site is mutated into arginine; and (c) the serine at the 199th site is mutated into aspartic acid, the serine at the 200th site is mutated into arginine, and the asparagine at the 240th site is mutated into tryptophan. The mutant is used for efficiently catalyzing reduction of HMF or furfural to respectively synthesize BHMF and furfuryl alcohol, so that the purposes of improving the production efficiency, reducing the production cost and improving the environmental effect are achieved.

The invention discloses a copper-rich phase high-entropy alloy and application thereof in urea synthesis, and belongs to the technical field of electro-catalysis. According to the method, serine and histidine functionalized and boron-doped graphene quantum dots (SHB-GQD) and a copper-rich phase are introduced, so that the urea synthesis electro-catalytic performance of the MnFeCoNiCu2.0 high-entropy alloy (MnFeCoNiCu2.0 HEA / SHB-GQD) is improved; the method disclosed by the invention is green and environment-friendly, simple and easy to implement and relatively low in cost, and shows excellent electrocatalytic activity and high stability. According to the MnFeCoNiCu2. 0HEA / SHB-GQD urea prepared by the preparation method disclosed by the invention, the synthesis rate reaches 59.01 mmol gcatalyst <-1 > h <-1 >; the Faraday efficiency reaches 26.6%; and the influence on the urea synthesis yield and the Faraday efficiency is small after the catalyst is recycled for 8 times.